Republic of MoldovaTuberculosis profile
Population  2016 4.1 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.26 (0.24–0.27) 6.3 (5.9–6.7)
Mortality (HIV+TB only) 0.062 (0.046–0.08) 1.5 (1.1–2)
Incidence  (includes HIV+TB) 4.1 (3.5–4.7) 101 (87–117)
Incidence (HIV+TB only) 0.37 (0.31–0.43) 9.2 (7.8–11)
Incidence (MDR/RR-TB)** 2.3 (1.9–2.6) 56 (47–65)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.19 (0.16–0.22) 1 (0.86–1.2) 1.2 (1–1.4)
Males 0.21 (0.18–0.25) 2.7 (2.3–3.1) 2.9 (2.5–3.3)
Total 0.4 (0.34–0.46) 3.7 (3.1–4.3) 4.1 (3.5–4.7)
TB case notifications, 2016  
Total cases notified 4 134
Total new and relapse 3 571
          - % tested with rapid diagnostics at time of diagnosis 51%
          - % with known HIV status 94%
          - % pulmonary 91%
          - % bacteriologically confirmed among pulmonary 62%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.08 (0.07–0.09)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 293 9%
          - on antiretroviral therapy 193 66%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  1 400
(1 300–1 400)
Estimated % of TB cases with MDR/RR-TB 26% (24–28) 56% (51–60)  
% notified tested for rifampicin resistance 58% 65% 2 491
MDR/RR-TB cases tested for resistance to second-line drugs   862
Laboratory-confirmed cases MDR/RR-TB: 1 031, XDR-TB: 72
Patients started on treatment **** MDR/RR-TB: 1 037, XDR-TB: 65
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 80% 2 992
Previously treated cases, excluding relapse, registered in 2015 47% 217
HIV-positive TB cases registered in 2015 55% 227
MDR/RR-TB cases started on second-line treatment in 2014 50% 919
XDR-TB cases started on second-line treatment in 2014 33% 9
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment 0%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2017  
National TB budget (US$ millions) 33
Funding source: 74% domestic, 18% international, 8% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-11-20 Data: www.who.int/tb/data